Eberhardt DR, Lee SH, Yin X, Balynas AM, Rekate EC, Kraiss JN, Lang MJ, Walsh MA, Streiff ME, Corbin AC, Li Y, Funai K, Sachse FB, Chaudhuri D. EFHD1 ablation inhibits cardiac mitoflash activation and protects cardiomyocytes from ischemia.
J Mol Cell Cardiol 2022;
167:1-14. [PMID:
35304170 PMCID:
PMC9107497 DOI:
10.1016/j.yjmcc.2022.03.002]
[Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/18/2021] [Revised: 02/23/2022] [Accepted: 03/11/2022] [Indexed: 12/07/2022]
Abstract
Altered levels of intracellular calcium (Ca2+) are a highly prevalent feature in different forms of cardiac injury, producing changes in contractility, arrhythmias, and mitochondrial dysfunction. In cardiac ischemia-reperfusion injury, mitochondrial Ca2+ overload leads to pathological production of reactive oxygen species (ROS), activates the permeability transition, and cardiomyocyte death. Here we investigated the cardiac phenotype caused by deletion of EF-hand domain-containing protein D1 (Efhd1-/-), a Ca2+-binding mitochondrial protein whose function is poorly understood. Efhd1-/- mice are viable and have no adverse cardiac phenotypes. They feature reductions in basal ROS levels and mitoflash events, both important precursors for mitochondrial injury, though cardiac mitochondria have normal susceptibility to Ca2+ overload. Notably, we also find that Efhd1-/- mice and their cardiomyocytes are resistant to hypoxic injury.
Collapse